1. Home
  2. BLFS vs TBPH Comparison

BLFS vs TBPH Comparison

Compare BLFS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioLife Solutions Inc.

BLFS

BioLife Solutions Inc.

HOLD

Current Price

$25.17

Market Cap

923.5M

Sector

Health Care

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.08

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLFS
TBPH
Founded
1987
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
923.5M
824.9M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
BLFS
TBPH
Price
$25.17
$16.08
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$32.00
$18.40
AVG Volume (30 Days)
519.2K
289.3K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
77.27
279.13
EPS
0.02
N/A
Revenue
$96,214,000.00
$15,386,000.00
Revenue This Year
$19.73
$8.46
Revenue Next Year
$17.82
N/A
P/E Ratio
$1,273.75
N/A
Revenue Growth
16.97
N/A
52 Week Low
$17.86
$9.98
52 Week High
$29.57
$21.03

Technical Indicators

Market Signals
Indicator
BLFS
TBPH
Relative Strength Index (RSI) 66.04 40.51
Support Level $23.74 $13.41
Resistance Level $26.39 $17.21
Average True Range (ATR) 1.10 0.34
MACD 0.28 -0.06
Stochastic Oscillator 87.16 4.84

Price Performance

Historical Comparison
BLFS
TBPH

About BLFS BioLife Solutions Inc.

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: